Adaptive Financial Statements From 2010 to 2023

ADPT Stock  USD 8.43  0.59  7.53%   
Adaptive Biotechnologies financial statements provide useful quarterly and yearly information to potential Adaptive Biotechnologies Corp investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Adaptive Biotechnologies financial statements helps investors assess Adaptive Biotechnologies' valuation, profitability, and current liquidity needs.
There are currently ninety-eight fundamental signals for Adaptive Biotechnologies Corp that can be evaluated and compared over time across rivals. Make sure you validate Adaptive Biotechnologies' prevailing fundamentals against the performance from 2010 to 2023 and make sure the trends continue to evolve in the right direction.
Adaptive Biotechnologies Net Income Per Employee is comparatively stable at the moment as compared to the past year. Adaptive Biotechnologies reported Net Income Per Employee of 3,715 in 2022. Average Assets is likely to gain to about 889.5 M in 2023, whereas Earnings before Tax are likely to drop (205.5 M) in 2023.
  
Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive main balance sheet or income statement drivers, such as Cost of Revenue of 48.6 M, Gross Profit of 108.5 M or Interest Expense of 3.8 M, as well as many exotic indicators such as Interest Coverage of 3.22, Long Term Debt to Equity of 1.84 or Calculated Tax Rate of 17.06. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules. It can also supplement Adaptive Biotechnologies' financial leverage analysis and stock options assessment as well as various Adaptive Biotechnologies Technical models . Check out the analysis of Adaptive Biotechnologies Correlation against competitors. For more information on how to buy Adaptive Stock please use our How to Invest in Adaptive Biotechnologies guide.

Adaptive Biotechnologies Revenues

157.09 Million

Adaptive Biotechnologies Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Trade and Non Trade Receivables43.2 M40.1 M12.3 M
Up
Slightly volatile
Property Plant and Equipment Net141.4 M164.2 M57.8 M
Up
Slightly volatile
Trade and Non Trade Payables6.5 M8.1 M3.1 M
Up
Slightly volatile
Liabilities Non Current248.3 M282.7 M93.8 M
Up
Slightly volatile
Current Liabilities101.3 M109.8 M49.9 M
Up
Slightly volatile
Total Liabilities349.6 M392.5 M143.7 M
Up
Slightly volatile
Investments Non Current269.4 M249.7 M81.2 M
Up
Slightly volatile
Investments Current396.6 M408.2 M216.3 M
Up
Slightly volatile
Investments440 M408.2 M256 M
Up
Slightly volatile
Inventory14.3 M14.5 M8.4 M
Up
Slightly volatile
Goodwill and Intangible Assets121 M125.8 M131.5 M
Down
Slightly volatile
Shareholders Equity USD427.6 M464.2 M53.9 M
Up
Slightly volatile
Shareholders Equity427.6 M464.2 M53.9 M
Up
Slightly volatile
Deferred Revenue146.3 M122.7 M77.9 M
Up
Slightly volatile
Total Debt USD193.7 M233.4 M72.3 M
Up
Slightly volatile
Debt Non Current186.2 M224.1 M70.5 M
Up
Slightly volatile
Debt Current8.3 M9.2 M4.4 M
Up
Slightly volatile
Total Debt193.7 M233.4 M72.3 M
Up
Slightly volatile
Cash and Equivalents USD106.4 M92.4 M93 M
Up
Slightly volatile
Cash and Equivalents106.4 M92.4 M93 M
Up
Slightly volatile
Assets Non Current330 M294.5 M231.7 M
Up
Slightly volatile
Current Assets555.5 M562.1 M334.5 M
Up
Slightly volatile
Total Assets885.4 M856.6 M566.2 M
Up
Slightly volatile
Accumulated Other Comprehensive Income(4.2 M)(4.1 M)(667.7 K)
Down
Slightly volatile

Adaptive Biotechnologies Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Weighted Average Shares Diluted124 M142.5 M51.2 M
Up
Slightly volatile
Weighted Average Shares124 M142.5 M51.2 M
Up
Slightly volatile
Selling General and Administrative Expense155.9 M184.1 M71.2 M
Up
Slightly volatile
Research and Development Expense126.9 M141.8 M63.8 M
Up
Slightly volatile
Revenues USD157.1 M185.3 M74.5 M
Up
Slightly volatile
Revenues157.1 M185.3 M74.5 M
Up
Slightly volatile
Preferred Dividends Income Statement Impact1.2 M1.1 M286.8 K
Up
Slightly volatile
Operating Expenses284.8 M327.6 M137.1 M
Up
Slightly volatile
Interest Expense3.8 M3.8 M4.2 M
Down
Slightly volatile
Gross Profit108.5 M127.4 M49.8 M
Up
Slightly volatile
Cost of Revenue48.6 M57.9 M24.7 M
Up
Slightly volatile

Adaptive Biotechnologies Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Share Based Compensation44.1 M55.5 M17.7 M
Up
Slightly volatile
Net Cash Flow from Operations(188.8 M)(183.9 M)(58.6 M)
Down
Slightly volatile
Net Cash Flow Investment Acquisitions and Disposals20.8 M19.3 M2.2 M
Down
Pretty Stable
Net Cash Flow from Investing3.1 M2.9 M(8.5 M)
Down
Pretty Stable
Net Cash Flow from Financing149.1 M132.3 M94.5 M
Up
Slightly volatile
Issuance Repayment of Debt Securities 111.3 M111.9 M122.6 M
Down
Slightly volatile
Issuance Purchase of Equity Shares8.1 M7.9 M47.5 M
Up
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(50.1 M)(48.8 M)26.4 M
Down
Slightly volatile
Depreciation Amortization and Accretion22.6 M28.1 M10.3 M
Up
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Tangible Assets Book Value per Share7.25.12814.4528
Down
Slightly volatile
Sales per Share1.521.32.5374
Down
Slightly volatile
Return on Average Equity(0.41)(0.396)(0.004)
Down
Slightly volatile
Price to Sales Ratio6.035.87625.6819
Down
Very volatile
Price to Book Value2.422.3546.24
Down
Slightly volatile
Gross Margin0.760.6870.6444
Up
Slightly volatile
Free Cash Flow per Share(1.52)(1.405)(2.1841)
Up
Slightly volatile
Debt to Equity Ratio0.910.8460.168
Up
Slightly volatile
Current Ratio5.585.128.2196
Down
Slightly volatile
Book Value per Share3.513.257(10.1979)
Up
Slightly volatile
Asset Turnover0.20.2180.1609
Up
Pretty Stable
Total Assets Per Share20.1922.7620.6113
Up
Slightly volatile
Cash Flow Per Share0.620.57(0.028)
Up
Slightly volatile
Return on Investment17.9816.6711.8311
Up
Slightly volatile
Operating Margin9.368.687.4991
Up
Slightly volatile
Calculated Tax Rate17.0618.9118.807
Up
Slightly volatile
Receivables Turnover8.78.117.5768
Down
Pretty Stable
Inventory Turnover80.2288.7278.1618
Down
Very volatile
PPandE Turnover3.464.03.6664
Up
Slightly volatile
Cash and Equivalents Turnover24.6928.7525.2644
Up
Slightly volatile
Accounts Payable Turnover18.2720.0619.859
Up
Slightly volatile
Accrued Expenses Turnover10.6511.5311.1763
Up
Slightly volatile
Interest Coverage3.223.173.1208
Down
Slightly volatile
Long Term Debt to Equity1.841.521.7095
Down
Slightly volatile
Quick Ratio0.941.130.9657
Up
Slightly volatile
Net Current Assets as percentage of Total Assets10.9810.187.7968
Up
Slightly volatile
Revenue to Assets0.60.620.6568
Up
Pretty Stable

Adaptive Biotechnologies Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Working Capital454.2 M452.4 M284.5 M
Up
Slightly volatile
Tangible Asset Value743.9 M730.8 M433.2 M
Up
Slightly volatile
Market Capitalization1.1 B1.1 B3.7 B
Down
Pretty Stable
Invested Capital Average625.3 M660.7 M285.6 M
Up
Slightly volatile
Invested Capital706.3 M762 M337.4 M
Up
Slightly volatile
Free Cash Flow(205.6 M)(200.3 M)(69.3 M)
Down
Slightly volatile
Enterprise Value1.1 B1.1 B3.6 B
Down
Pretty Stable
Average Equity467.7 M505.9 M19.7 M
Up
Slightly volatile
Average Assets889.5 M851.4 M534.5 M
Up
Slightly volatile
Revenue Per Employee100.3 K102.5 K109.1 K
Up
Pretty Stable
Net Income Per EmployeeK3.7 K1.6 K
Up
Slightly volatile

Adaptive Fundamental Market Drivers

Cash And Short Term Investments498.2 M

Adaptive Upcoming Events

3rd of May 2023
Upcoming Quarterly Report
View
2nd of August 2023
Next Financial Report
View
31st of March 2023
Next Fiscal Quarter End
View
13th of February 2024
Next Fiscal Year End
View
31st of December 2022
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Adaptive Biotechnologies Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Adaptive Biotechnologies income statement, its balance sheet, and the statement of cash flows. Adaptive Biotechnologies investors use historical funamental indicators, such as Adaptive Biotechnologies's revenue or net income, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may use each financial statement separately, they are all related. The changes in Adaptive Biotechnologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adaptive Biotechnologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Adaptive Biotechnologies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Adaptive Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2023
Deferred Revenue122.7 M146.3 M
Cost of Revenue57.9 M48.6 M
Revenues185.3 M157.1 M
Revenue to Assets 0.62  0.60 
Revenue Per Employee102.5 K100.3 K

Adaptive Biotechnologies Investors Sentiment

The influence of Adaptive Biotechnologies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Adaptive. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Adaptive Biotechnologies' public news can be used to forecast risks associated with investment in Adaptive. The trend in average sentiment can be used to explain how an investor holding Adaptive can time the market purely based on public headlines and social activities around Adaptive Biotechnologies Corp. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Adaptive Biotechnologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Adaptive Biotechnologies' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Adaptive Biotechnologies' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Adaptive Biotechnologies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Adaptive Biotechnologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Adaptive Biotechnologies' short interest history, or implied volatility extrapolated from Adaptive Biotechnologies options trading.

Pair Trading with Adaptive Biotechnologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.

Moving against Adaptive Biotechnologies

-0.7ABBVAbbVie Inc Fiscal Quarter End 31st of March 2023 PairCorr
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out the analysis of Adaptive Biotechnologies Correlation against competitors. For more information on how to buy Adaptive Stock please use our How to Invest in Adaptive Biotechnologies guide. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for analysis

When running Adaptive Biotechnologies price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
Bond Directory
Find actively traded corporate debentures issued by US companies
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.41) 
Revenue Per Share
1.3
Quarterly Revenue Growth
0.455
Return On Assets
(0.14) 
Return On Equity
(0.38) 
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine Adaptive Biotechnologies value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.